Potential role of the antiproliferative cytokine beta-galactoside binding protein in cancer therapy.
This review highlights the discovery of beta-galactoside binding protein (betaGBP), an antiproliferative cytokine, as a potent and selective anticancer agent. Unlike drugs designed to block receptor tyrosine kinases or specific control points along signaling pathways, betaGBP does not harm normal cells. As a physiological effector molecule, betaGBP can selectively induce death in cancer cells by enforcing its regulatory functions to which normal and cancer cells respond differently, and thus exploit the genetic and molecular deviations developed by cancer cells.